Targeting liposomes loaded with melphalan prodrug to tumour vasculature via the Sialyl Lewis X selectin ligand

References

• Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320–30
   PubMed Web of Science ®Google Scholar
• Schiffelers R, Storm G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int J Pharm 2008;364:258–64
   PubMed Web of Science ®Google Scholar
• Fens MHAM, Hill KJ, Issa J, et al. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer 2008;99:1256–64
   PubMed Web of Science ®Google Scholar
• Vader P, Crielaard BJ, Van Dommelen SM, et al. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. J Control Release 2012;160:211–6
   PubMed Web of Science ®Google Scholar
• Wicki A, Rochlitz C, Orleth A, et al. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 2012;18:454–64
   PubMed Web of Science ®Google Scholar
• Ehrhardt C, Kneuer C, Bakowsky U. Selectins – an emerging target for drug delivery. Adv Drug Deliv Rev 2004;56:527–49
   PubMed Web of Science ®Google Scholar
• Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev 2008;27:19–30
   PubMed Web of Science ®Google Scholar
• Barthel S, Gavino J, Descheny L, Dimitroff C. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007;11:1473–91
   PubMed Web of Science ®Google Scholar
• Köhler S, Ullrich S, Richter U, Schumacher U. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer 2010;102:602–9
   PubMed Web of Science ®Google Scholar
• Jubeli E, Moine L, Vergnaud-Gauduchon J, Barratt G. E-selectin as a target for drug delivery and molecular imaging. J Control Release 2012;158:194–206
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Tian R, Li Y, et al. Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin. Ann Surg 2011;254:450–6
   PubMed Web of Science ®Google Scholar
• Foxall C, Watson SR, Dowbenko D, et al. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J Cell Biol 1992;117:895–902
   PubMed Web of Science ®Google Scholar
• Vodovozova EL, Moiseeva EV, Grechko GK, et al. Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLe(X), in a mouse mammary adenocarcinoma model. Eur J Cancer 2000;36:942–9
   PubMed Web of Science ®Google Scholar
• Kuznetsova N, Kandyba A, Vostrov I, et al. Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles. J Drug Deliv Sci Tech 2009;19:51–9
   Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;85:6949–53
   PubMed Web of Science ®Google Scholar
• Peng A, Straubinger RM, Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 2010;12:473–81
   PubMed Web of Science ®Google Scholar
• Kuznetsova NR, Sevrin C, Lespineux D, et al. Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer. J Control Release 2012;160:394–400
   PubMed Web of Science ®Google Scholar
• Vodovozova EL, Pazynina GV, Bovin NV. Synthesis of diglyceride conjugate of selectin ligand SiaLeX as a vector for targeting of drug-loaded liposomes. Mendeleev Commun 2011;21:69–71
   Web of Science ®Google Scholar
• Vodovozova EL, Nikol’skii PI, Mikhalev II, Molotkovskii IG. Lipid derivatives of sarcolysin, methotrexate and rubomycin. Russ J Bioorg Chem 1996;22:468–75
   Google Scholar
• Boldyrev IA, Zhai X, Momsen MM, et al. New BODIPY lipid probes for fluorescence studies of membranes. J Lipid Res 2007;48:1518–32
   PubMed Web of Science ®Google Scholar
• Khromova NV, Kopnin PB, Stepanova EV, et al. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett 2009;276:143–51
   PubMed Web of Science ®Google Scholar
• Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs 2013;31:1436--43
   Google Scholar
• Wang D, Stockard CR, Harkins L, et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 2008;83:179–89
   PubMed Web of Science ®Google Scholar
• Ullrich RT, Jikeli JF, Diedenhofen M, et al. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS One 2011;6:e19592
   PubMedGoogle Scholar
• Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363–80
   PubMed Web of Science ®Google Scholar
• Hirai M, Minematsu H, Kondo N, et al. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun 2007;353:553–8
   PubMed Web of Science ®Google Scholar
• Phillips M, Gran M, Peppas N. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010;5:143–59
   PubMed Web of Science ®Google Scholar
• Hirai M, Minematsu H, Hiramatsu Y, et al. Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm 2010;391:274–83
   PubMed Web of Science ®Google Scholar
• Musto P, D’Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs 2007;16:1467–87
   PubMed Web of Science ®Google Scholar
• Mateos MV, San-Miguel J. Treatment of newly diagnosed myeloma in patients not eligible for transplantation. Curr Hematol Malig Rep 2011;6:113–19
   PubMedGoogle Scholar
• Krasnov VP, Korolyova MA, Vodovozova EL. Nano-sized melphalan and sarcolysin drug delivery systems: synthesis and prospects of application. Russ Chem Rev 2013;82:783–814
   Web of Science ®Google Scholar
• Murohara T, Margiotta J, Phillips LM, et al. Cardioprotection by liposome-conjugated sialyl Lewis x-oligosaccharide in myocardial ischaemia and reperfusion injury. Cardiovasc Res 1995;30:965–74
   PubMed Web of Science ®Google Scholar
• DeFrees SA, Phillips L, Guo L, Zalipsky S. Sialyl Lewis x liposomes as a multivalent ligand and inhibitor of E-selectin mediated cellular adhesion. J Am Chem Soc 1996;118:6101–4
   Web of Science ®Google Scholar
• Zeisig R, Stahn R, Wenzel K, et al. Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro. Biochim Biophys Acta 2004;1660:31–40
   PubMed Web of Science ®Google Scholar